This sheet is about exposure to oxcarbazepine in pregnancy or while breastfeeding. This information is based on available published literature. It should not take the place of medical care and advice from your healthcare provider.

What is oxcarbazepine?

Oxcarbazepine is a medication that has been approved for the treatment of partial seizures. It has also been used to treat migraine, symptoms of dementia, epilepsy, trigeminal neuralgia (nerve pain in the face) and bipolar disorder. Some brand names for oxcarbazepine are Trileptal^® and Oxtellar XR^®.

Sometimes when women find out they are pregnant, they think about changing how they take their medication, or stopping their medication altogether. However, it is important to talk with your healthcare providers before making any changes to how you take your medication. Having a seizure while pregnant could be harmful to the woman who is pregnant as well as to the pregnancy. People who have bipolar disorder and stop taking their medication are at increased risk for episodes of depression or mania that may be harmful to both the woman who is pregnant and the fetus.

Women should discuss their options for treatment, including medications, with their healthcare providers before getting pregnant when possible. Women who want to become pregnant should also discuss taking a folic acid supplement with their healthcare providers.

I take oxcarbazepine. Can it make it harder for me to get pregnant?

Studies have not been done in humans to see if oxcarbazepine can make it harder to get pregnant. Having a seizure disorder, as well as long-term use of seizure medications, might make it harder to get pregnant.

Does taking oxcarbazepine increase the chance of miscarriage?

Miscarriage is common and can occur in any pregnancy for many different reasons. One study did not find a higher rate of miscarriage among 337 women with epilepsy who took oxcarbazepine compared to those with epilepsy who took other medications.

Does taking oxcarbazepine increase the chance of birth defects?

Birth defects can happen in any pregnancy for different reasons. Out of all babies born each year, about 3 out of 100 (3%) will have a birth defect. Animal studies suggest that oxcarbazepine might increase the chance of birth defects. However, reports on almost 2,600 human pregnancies have not suggested a significantly increased chance of birth defects when oxcarbazepine is used. The chance for birth defects might increase when other anticonvulsant medications are used with oxcarbazepine.

Does taking oxcarbazepine increase the chance of other pregnancy-related problems?

Animal studies have suggested that oxcarbazepine might increase the chance of lower birth weight. One human report also found low birth weight (weighing less than 5 pounds, 8 ounces [2500 grams] at birth) in 7 out of 8 newborns exposed to oxcarbazepine in pregnancy. However, this report also found that low birth weight was more common among infants born to women with epilepsy. Another study of 94 infants did not suggest that exposure to oxcarbazepine at any point in pregnancy increased the chance of low birth weight.

In rare cases, taking anticonvulsant medications during pregnancy, including oxcarbazepine, can cause bleeding problems in the newborn due to low vitamin K levels. Women taking oxcarbazepine in pregnancy should talk with their healthcare providers about taking vitamin K supplements near the end of their pregnancies. They can also talk to their child’s pediatrician before delivery about giving the newborn a vitamin K supplement at birth.

I need to take oxcarbazepine throughout my entire pregnancy. Will it cause withdrawal symptoms in my baby after birth?

It is not known if oxcarbazepine can cause withdrawal symptoms in a baby after birth. There are 2 case reports of newborns exposed to oxcarbazepine in pregnancy who had possible withdrawal symptoms after delivery. The symptoms went away after 9 to 12 days and included poor feeding, tremors, irritability, sneezing, and a high-pitched cry. Two case reports are not enough to know if oxcarbazepine was the cause of these symptoms. In contrast, a study of 94 infants exposed to oxcarbazepine at any point in pregnancy did not find an increased risk for withdrawal symptoms compared to infants not exposed to oxcarbazepine.

Does taking oxcarbazepine in pregnancy affect future behavior or learning for the child?

It is unclear if using oxcarbazepine in pregnancy can increase the chance of behavior or learning issues in children. One study looking at women taking anticonvulsant medications during pregnancy (only 10 took oxcarbazepine) found delayed verbal skills in infants evaluated at age 7 months. Another study that evaluated children at ages 6-14 years suggested an increased chance of intellectual disability after prenatal exposure to anticonvulsant medications including oxcarbazepine. However, other studies have found no differences in neurodevelopment, learning ability, or need for speech therapy in children exposed to oxcarbazepine compared to children exposed to some other anticonvulsant medications or those not exposed to these medications at all.

Breastfeeding while taking oxcarbazepine:

Oxcarbazepine passes into breast milk. Eleven case reports found very low levels of the medication in the blood of breastfed infants. Seventeen case reports describe healthy children with no side effects after being exposed to oxcarbazepine through breast milk. If you suspect the baby has any symptoms (being very sleepy, unable to wake for feeds, or poor weight gain), contact the child’s healthcare provider. Be sure to talk to your healthcare provider about all your breastfeeding questions.

If a man takes oxcarbazepine, could it affect fertility or increase the chance of birth defects?

It is not known if taking oxcarbazepine can affect a man’s fertility (ability to get a woman pregnant). Men who have epilepsy might have reduced sperm quality and sexual function. This makes it hard to know if effects on male sexual function and fertility are related to the medication, to the underlying condition, or other factors. In general, exposures that men have are unlikely to increase risks to a pregnancy. For more information, please see the MotherToBaby fact sheet on Paternal Exposures at https://mothertobaby.org/fact-sheets/paternal-exposures-pregnancy/.

Selected References:

• Artama M, et al. 2006. Antiepileptic drug use and birth rate in patients with epilepsy-a population-based cohort study in Finland. Hum Reprod 21:2290-5. [PubMed: 16751648]
• Bech LF, et al. 2018. In utero exposure to antiepileptic drugs is associated with learning disabilities among offspring. J Neurol Neurosurg Psychiatry 89:1324–1331. [PubMed: 30076271]
• Birnbaum AK, et al. 2020. Antiepileptic drug exposure in infants of breastfeeding mothers with epilepsy. JAMA Neurol 77(4):441-450. [PMC free article: PMC6990802] [PubMed: 31886825]
• Bjork M-H, et al. 2022. Association of prenatal exposure to antiseizure medication with risk of autism and intellectual disability. JAMA Neurology 79(7):672-81. [PubMed: 35639399]
• Blotière PO, et al. 2019. Risks of 23 specific malformations associated with prenatal exposure to 10 antiepileptic drugs. Neurology 93(2):e167-e80. [PMC free article: PMC6656651] [PubMed: 31189695]
• Blotière PO, et al. 2020. Risk of early neurodevelopmental outcomes associated with prenatal exposure to the antiepileptic drugs most commonly used during pregnancy: a French nationwide population-based cohort study. BMJ Open 10(6):e034829. [PMC free article: PMC7282331] [PubMed: 32513880]
• Bruno MK, Harden CL. 2002. Epilepsy in pregnant women. Curr Treat Options Neurol 4(1):31-40. [PubMed: 11734102]
• Bülau P, et al. 1988. Pharmacokinetics of oxcarbazepine and 10-hydroxy-carbazepine in the newborn child of an oxcarbazepine-treated mother. Eur J Clin Pharmacol 34:311–3. [PubMed: 3396622]
• Chen CY, et al. 2017. In utero oxcarbazepine exposure and neonatal abstinence syndrome: Case report and brief review of the literature. Pharmacotherapy 37:e71–e5. [PMC free article: PMC5575550] [PubMed: 28543284]
• Christensen J, et al. 2015. Apgar-score in children prenatally exposed to antiepileptic drugs: a population-based cohort study. BMJ Open 5(9):e007425. [PMC free article: PMC4567672] [PubMed: 26359281]
• Cohen JM, et al. 2019. Anticonvulsant mood stabilizer and lithium use and risk of adverse pregnancy outcomes. J Clin Psychiatry 2019;80(4). [PubMed: 31237992]
• Cohen JM, et al. 2023. Comparative safety of antiseizure medication monotherapy for major malformations. Ann Neurol. 93(3):551-562. [PubMed: 36433783]
• Daugaard CA, et al. 2020. Association of prenatal exposure to valproate and other antiepileptic drugs with intellectual disability and delayed childhood milestones. JAMA Netw Open 3(11):e2025570. [PMC free article: PMC7656282] [PubMed: 33170264]
• Dreier JW et al. 2023. Prenatal exposure to antiseizure medication and incidence of childhood- and adolescence-onset psychiatric disorders. JAMA Neurology 80(6):568-577. [PMC free article: PMC10111234] [PubMed: 37067807]
• Eisenschenk S. 2006. Treatment with oxcarbazepine during pregnancy. Neurologist 12(5):249-254. [PubMed: 16990737]
• Friis ML, et al. 1993. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 87(3):224-227. [PubMed: 8475694]
• Gentile S. 2003. Oxcarbazepine in pregnancy and lactation. Clin Drug Investig 23:687. [PubMed: 17535084]
• Guo Y, et al. 2021. A comparative study of the effects of valproate and oxcarbazepine on sexual function, sperm quality, and sex hormones in males with epilepsy. Biomed Res Int 2021:6624101. [PMC free article: PMC8275390] [PubMed: 34285917]
• Hvas CL, et al. 2000. Epilepsy and pregnancy: effect of antiepileptic drugs and lifestyle on birthweight. Br J Obstet Gynaecol 107:896-902. [PubMed: 10901562]
• Isojarvi JI, et al. 2004. Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology 62:247-53. [PubMed: 14745062]
• Jacobsen PE, et al. 2014. Prenatal exposure to antiepileptic drugs and dental agenesis. PLoS One 9(1):e84420. [PMC free article: PMC3885552] [PubMed: 24416231]
• Johnson K, et al. 2021. Retrospective Analysis of Oxcarbazepine in Pregnant Women With Substance Use Disorders: Focus on Safety. Journal of Pharmacy Practice 34(1):28-34. [PubMed: 31232158]
• Kaaja E, et al. 2003. Major malformations in offspring of women with epilepsy. Neurology 60:575-9. [PubMed: 12601095]
• Lloyd P, et al. 1994. Clinical Pharmacology and Pharmacokinetics of Oxcarbazepine. Epilepsia 35(s3). [PubMed: 8156973]
• Luef G, et al. 2009. Oxcarbazepine treatment in male epilepsy patients improves pre-existing sexual dysfunction. Neurologica 119(2):94-99. [PubMed: 18705676]
• Lutz UC, et al. 2007. Oxcarbazepine treatment during breast-feeding: a case report. J Clin Psychopharmacol 27:730–2. [PubMed: 18004156]
• Meischenguiser R, et al. 2003. Major malformations in offspring of women with epilepsy. [Letter] Neurology 61:1631. [PubMed: 14732941]
• Meischenguiser R, et. al. 2004. Oxcarbazepine in pregnancy: clinical experience in Argentina. Epilepsy Behav 5:163-167. [PubMed: 15123016]
• Miller M, et al. 2003. Major malformations in offspring of women with epilepsy. [Letter] Neurology 61:1631. [PubMed: 14663064]
• Mølgaard-Nielsen D, Hviid A. 2011. Newer-generation antiepileptic drugs and the risk of major birth defects. JAMA 305(19):1996-2002. [PubMed: 21586715]
• Montouris G. 2005. Safety of the newer antiepileptic drug oxcarbazepine during pregnancy. Curr Med Res Opin 21:693-701. [PubMed: 15969868]
• Novartis. 2020. Trileptal® Prescribing Information. Available at URL: https://www​.novartis​.us/sites/www.novartis​.us/files/trileptal.pdf.
• Ohman I, et al. 2009. Pharmacokinetics of oxcarbazine in neonatal period and during lactation. Epilepsia 50(Suppl. 4):238. Abstract.
• Rolnitsky A, et al. 2013. In utero oxcarbazepine and a withdrawal syndrome, anomalies, and hyponatremia. Pediatr Neurol 2013;48(6):466-8. [PubMed: 23668873]
• Supernus Pharmaceuticals. 2018. Otexllar XR® Prescribing Information. Available at URL: https://www​.oxtellarxrhcp​.com/assets/OxtellarXRPrescribingInformation.pdf.
• Tomson T, et al. 2015. Antiepileptic drugs and intrauterine death: A prospective observational study from EURAP. Neurology 85: 580-588. [PubMed: 26187231]
• Tomson T, et al. 2018. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 17(6):530-538. [PubMed: 29680205]
• Trivedi M, et al. 2018. Spontaneous fetal loss in women with epilepsy: prospective data from pregnancy registry in India. Epilepsy Research 146:50-53. [PubMed: 30077056]
• Vajda F, et al. 2018. Anti-epieptic drug exposure and risk of foetal death in utero. Acta Neurol Scand 137(1):20-23. [PubMed: 28857118]
• Veiby G, et al. 2014. Fetal growth restriction and birth defects with newer and older antiepileptic drugs during pregnancy. J Neurol 261:579-588. [PubMed: 24449062]
• Videman M, et al. 2016. Evidence for spared attention to faces in 7-month-old infants after prenatal exposure to antiepileptic drugs. Epilepsy Behav 64(Pt A):62-68. [PubMed: 27732918]
• Weston J, et al. 2016. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev 11(5):CD010224. [PMC free article: PMC6465055] [PubMed: 27819746]
• Wu D, et al. 2018. The effects of oxcarbazepine, levetiracetam, and lamotrigine on semen quality, sexual function, and sex hormones in male adults with epilepsy. Epilepsia 59(7):1344-1350. [PubMed: 29889310]
• Yin X, et al. 2022.Pharmacokinetic changes for newer antiepileptic drugs and seizure control during pregnancy. CNS Neurosci Ther. 28(5):658-66. [PMC free article: PMC8981429] [PubMed: 35037389]